Lymphoma Clinical Trials in Houston, Texas

125 recruitingHouston, Texas

Showing 120 of 125 trials

Recruiting
Phase 3

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features
National Cancer Institute (NCI)600 enrolled260 locationsNCT06337318
Recruiting
Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled399 locationsNCT05675410
Recruiting
Phase 2

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

Nodular Lymphocyte Predominant B-Cell LymphomaRecurrent Nodular Lymphocyte Predominant B-Cell LymphomaRefractory Nodular Lymphocyte Predominant B-Cell Lymphoma
National Cancer Institute (NCI)70 enrolled35 locationsNCT05886036
Recruiting
Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma
Hoffmann-La Roche121 enrolled26 locationsNCT05169515
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 1Phase 2

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Mantle Cell LymphomaB-cell Lymphoma
BeOne Medicines300 enrolled149 locationsNCT06742996
Recruiting
Phase 1

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma+1 more
AstraZeneca317 enrolled27 locationsNCT04594642
Recruiting
Phase 3

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled166 locationsNCT02693535
Recruiting
Phase 1Phase 2

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled49 locationsNCT06634589
Recruiting
Phase 2

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Large B-cell Lymphoma
Allogene Therapeutics250 enrolled61 locationsNCT06500273
Recruiting
Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 3

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Lymphoma, T-CellPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc.150 enrolled17 locationsNCT06561048
Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 2

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Hodgkin LymphomaB-cell LymphomaRelapsed B-cell NHL
M.D. Anderson Cancer Center36 enrolled1 locationNCT05615636
Recruiting
Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled246 locationsNCT06717347
Recruiting
Phase 2

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Small Lymphocytic LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC320 enrolled73 locationsNCT05963074
Recruiting
Phase 2

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

T-cell Acute Lymphoblastic LeukemiaT-Cell Lymphoblastic Lymphoma
M.D. Anderson Cancer Center22 enrolled1 locationNCT06561074
Recruiting
Phase 1Phase 2

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Lymphoma
M.D. Anderson Cancer Center60 enrolled1 locationNCT05683171